Verrica Pharmaceuticals Inc. Contract Liability (Deferred Revenue)
Verrica Pharmaceuticals Inc. (VRCA) had Contract Liability (Deferred Revenue) of $1.33 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Deferred Revenue, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-08-06
- 2026-06-30: Contract with Customer, Liability, Current $1.33M.
- 2026-03-31: Contract with Customer, Liability, Current $1.03M.
- 2025-12-31: Contract with Customer, Liability, Current $782.00K.
- 2025-09-30: Contract with Customer, Liability, Current $1.56M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2026-06-30 | $1.33M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $1.03M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $782.00K 10-Q · filed 2026-08-06 |
| 2025-09-30 | $1.56M 10-Q · filed 2025-11-14 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |